Search results
Results from the WOW.Com Content Network
Standardized treatment regimen composed of multiple anti-Tuberculosis drugs are provided through the program. Typically, drug regimen consist of an intensive phase of about two to six months and a longer continuation phase of four to one and half years. [citation needed]
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
Tuberculosis is one of India's biggest health issues, but what makes this problem even worse is the recent discovery of Totally Drug-Resistant Tuberculosis, TDR-TB. This issue of drug resistance began with MDR-TB , moved to XDR-TB and, as of 2021, has grown to embrace the most dangerous form, TDR-TB .
Treatment with anti-TB drugs for at least 6 months results in higher success rates when compared with treatment less than 6 months, even though the difference is small. Shorter treatment regimen may be recommended for those with compliance issues. [146]
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
Extensively drug resistant tuberculosis is tuberculosis that is resistant to isoniazid and rifampicin, any fluoroquinolone, and any of the three second line injectable TB drugs (amikacin, capreomycin, and kanamycin). [1] TDR-TB has been identified in three countries; India, Iran, and Italy. The term was first presented in 2006, in which it ...
The goal of tuberculosis elimination is hampered by the lack of rapid testing, short and effective treatment courses, and completely effective vaccine. [2] The WHO as well as the Stop TB Partnership aim for the full elimination of TB by 2050—requiring a 1000-fold reduction in tuberculosis incidence. [ 3 ]
For treatment of RR- and MDT-TB, WHO treatment guidelines are as follows: "a regimen with at least five effective TB medicines during the intensive phase is recommended, including pyrazinamide and four core second-line TB medicines – one chosen from Group A, one from Group B, and at least two from Group C3 (conditional recommendation, very ...